An Introduction to PARSORTIX

Presented by:Andrew Newland, Chief ExecutiveShane Booth, CEO, Parsortix

7 October 2011

© ANGLE plc 2011

Parsortix

Patented technology for separating rare cells from blood

Page 2

Major medical diagnostic development for ANGLE

Forward-Looking StatementsThis presentation and the associated commentary contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently available to the Company; and ANGLE / Parsortix's actual results could differ materially from those stated or implied, due to risks and uncertainties associated with its business.

Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “potential”, “target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. ANGLE assumes no obligation to update the information included in this presentation, whether as a result of new information, future events or otherwise.

© ANGLE plc 2011 Page 3

Market for circulating tumour cell (CTC) separation device

Use of CTC cell counting (simple product) for:

− Research product (does not need regulatory approval)

− Monitoring patient response to chemotherapy

− Monitoring patients in remission to identify CTC ahead of secondary tumours

1.2 million new cancer patients per annum in the US market alone*

− Each patient may need to be monitored over 30 times

Target: potential therapeutic application for a product recovering cells

− A pressing need for CTC recovery in relation to lung, pancreatic, and colo-rectal cancers as tumour access for biopsy difficult

− These cancers account for approximately one third of the total number of cases annually in the US

ANGLE may develop the product initially cancer by cancer

*Source : US National Cancer Institute in 2010

© ANGLE plc 2011 Page 4

Parsortix: separation cassette schematic

Cassette components

Fully assembled cassette

Cassette housing

© ANGLE plc 2011 Page 5

Captured cells: whole blood control and spiked with SK-Br-3

Control

Spiked with breast cancer cells

© ANGLE plc 2011

Chromogenic staining of SK-Br-3 cells

Visual ID breast cancer cells

Stained breast Cancer cells

Identified cells marked using cytokeratin-18

© ANGLE plc 2011 Page 7

Development Plan

Finalise work on characterising the separation device including flow and volume capability

Finalise market requirements for device

Optimise design of separation device (next generation)

Establish collaboration with cancer research centre(s)

Separation of CTCs from cancer patient blood

Beta test next generation separation device

Final design of separation device

Manufacture in quantity

Initiate sales for research purposes

Target for completion mid 2012

© ANGLE plc 2011 Page 8

Newsflow potential

= key value triggers

Quarter ended 31-Oct-11 31-Jan-12 30-Apr-12 31-Jul-12 31-Oct-12 31-Jan-13 30-Apr-13 31-Jul-13

Parsortix

Validation of initial findings

(completed)

Establish collaborative research with leading Cancer Centres in the US and UK

Capture CTCs in cancer patient blood

Optimise separation cassette and consumable design

Advance discussions with Corporate Partners

Establish world leading Scientific Advisory Board

Initiate sales for research purposes

Continue and expand sales for research purposes

Comparative studies to support FDA and CE Mark submission

FDA/CE Mark approval

Corporate deal/ distribution partner finalised Target for

clinical product launch and sales

Acolyte Biomedica

Completion of Acolyte case

ANGLE decision on case against 3M

Potential for 3M settlement

GeomericsLaunch of Battlefield3 and Need for Speed

Completion of milestone 3 for major corporate

Potential for trade sale

NovocellusRetrospective study results

Potential for milestone payments

Prospective study results

Potential for product sales and royalties

Consider joint development programmes with Corporate Partners

Judgement on Acolyte case

© ANGLE plc 2011 Page 9

Near-term commercial potential

Target sales launch of product for research purposes mid 2012

− No requirement for regulatory approval

− Immediate market potential

− Astra Zeneca 20,000 separations p.a. with one research lab

− Early sales potential $25m p.a.

Target FDA approval of product for clinical use mid 2013

Clinical market for “simple counting product” estimated at $4bn p.a. in US market alone

Gross margin in excess of 75%

Significant corporate interest for collaboration with more complex products

The key is a simple, effective product

© ANGLE plc 2011 Page 10

Legal disclaimer

The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness.

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided torecipients on the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution could result in violation of the laws of such countries.

This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose whatsoever on the information, representation or opinions.

This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.